Opko Health Inc. (OPK) Expected to Post Earnings of -$0.08 Per Share

Wall Street analysts expect Opko Health Inc. (NASDAQ:OPK) to report ($0.08) earnings per share (EPS) for the current quarter, Zacks reports. Three analysts have made estimates for Opko Health’s earnings, with estimates ranging from ($0.11) to ($0.07). Opko Health also reported earnings of ($0.08) per share in the same quarter last year. The firm is expected to issue its next earnings results on Wednesday, November 14th.

According to Zacks, analysts expect that Opko Health will report full year earnings of ($0.23) per share for the current financial year, with EPS estimates ranging from ($0.29) to ($0.18). For the next year, analysts forecast that the business will post earnings of ($0.20) per share, with EPS estimates ranging from ($0.34) to ($0.03). Zacks’ earnings per share calculations are an average based on a survey of research analysts that that provide coverage for Opko Health.

Opko Health (NASDAQ:OPK) last released its quarterly earnings data on Tuesday, August 7th. The biotechnology company reported ($0.01) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.07) by $0.06. The business had revenue of $263.69 million for the quarter, compared to analysts’ expectations of $260.37 million. Opko Health had a negative return on equity of 9.32% and a negative net margin of 31.73%.

OPK has been the topic of a number of research reports. ValuEngine upgraded Opko Health from a “sell” rating to a “hold” rating in a research report on Friday, September 7th. BidaskClub upgraded Opko Health from a “buy” rating to a “strong-buy” rating in a research report on Friday, August 24th. Barrington Research restated a “buy” rating and set a $7.00 price objective on shares of Opko Health in a research report on Friday, October 5th. Finally, Cantor Fitzgerald restated a “buy” rating and set a $20.00 price objective on shares of Opko Health in a research report on Tuesday, August 7th. One research analyst has rated the stock with a sell rating, two have given a hold rating and three have given a buy rating to the stock. Opko Health has a consensus rating of “Hold” and a consensus price target of $9.69.

Shares of OPK traded down $0.08 on Friday, reaching $3.59. 3,255,600 shares of the stock traded hands, compared to its average volume of 5,552,234. The stock has a market cap of $2.13 billion, a PE ratio of -13.10 and a beta of 2.18. The company has a current ratio of 1.05, a quick ratio of 0.90 and a debt-to-equity ratio of 0.03. Opko Health has a 12 month low of $2.66 and a 12 month high of $6.99.

In related news, CEO Phillip Md Et Al Frost purchased 90,000 shares of the stock in a transaction on Thursday, July 26th. The shares were purchased at an average cost of $5.06 per share, for a total transaction of $455,400.00. Following the completion of the transaction, the chief executive officer now directly owns 3,068,951 shares of the company’s stock, valued at approximately $15,528,892.06. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Insiders acquired 225,000 shares of company stock worth $1,210,850 over the last quarter. Company insiders own 42.74% of the company’s stock.

A number of large investors have recently made changes to their positions in OPK. Wells Fargo & Company MN grew its position in Opko Health by 10.1% in the first quarter. Wells Fargo & Company MN now owns 537,283 shares of the biotechnology company’s stock valued at $1,703,000 after acquiring an additional 49,320 shares during the period. Schwab Charles Investment Management Inc. grew its position in Opko Health by 2.9% in the first quarter. Schwab Charles Investment Management Inc. now owns 1,607,078 shares of the biotechnology company’s stock valued at $5,095,000 after acquiring an additional 45,074 shares during the period. Northern Trust Corp boosted its stake in Opko Health by 4.0% in the first quarter. Northern Trust Corp now owns 1,750,676 shares of the biotechnology company’s stock worth $5,549,000 after purchasing an additional 66,562 shares in the last quarter. New York State Common Retirement Fund boosted its stake in Opko Health by 4.5% in the first quarter. New York State Common Retirement Fund now owns 751,978 shares of the biotechnology company’s stock worth $2,384,000 after purchasing an additional 32,203 shares in the last quarter. Finally, Russell Investments Group Ltd. boosted its stake in Opko Health by 17,876.0% in the first quarter. Russell Investments Group Ltd. now owns 110,013 shares of the biotechnology company’s stock worth $349,000 after purchasing an additional 109,401 shares in the last quarter. Hedge funds and other institutional investors own 24.70% of the company’s stock.

Opko Health Company Profile

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals business in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates Bio-Reference Laboratories, a clinical laboratory that offers laboratory testing services in the detection, diagnosis, evaluation, monitoring, and treatment of diseases.

See Also: How Do You Make Money With Penny Stocks?

Get a free copy of the Zacks research report on Opko Health (OPK)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Opko Health (NASDAQ:OPK)

Receive News & Ratings for Opko Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opko Health and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply